Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Equity Average (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Equity Average for 6 consecutive years, with $966.7 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 15.16% to $966.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $966.7 million through Dec 2025, up 15.16% year-over-year, with the annual reading at $989.8 million for FY2025, 44.8% up from the prior year.
  • Equity Average for Q4 2025 was $966.7 million at Janux Therapeutics, down from $983.5 million in the prior quarter.
  • The five-year high for Equity Average was $1.0 billion in Q1 2025, with the low at -$15.7 million in Q1 2021.
  • Average Equity Average over 5 years is $510.5 million, with a median of $366.4 million recorded in 2021.
  • The sharpest move saw Equity Average surged 3165.06% in 2021, then fell 12.74% in 2023.
  • Over 5 years, Equity Average stood at $371.5 million in 2021, then dropped by 12.22% to $326.1 million in 2022, then rose by 6.29% to $346.6 million in 2023, then skyrocketed by 142.16% to $839.4 million in 2024, then increased by 15.16% to $966.7 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $966.7 million, $983.5 million, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.